| Literature DB >> 33444321 |
Jason Ptacek1, Rachael E Hawtin1, Dongmei Sun2, Brent Louie1, Erik Evensen1, Barbara B Mittleman1, Alessandra Cesano1, Guy Cavet1, Clifton O Bingham3, Stacey S Cofield2, Jeffrey R Curtis2, Maria I Danila2, Chander Raman2, Richard A Furie4, Mark C Genovese5, William H Robinson5, Marc C Levesque6, Larry W Moreland7, Peter A Nigrovic8, Nancy A Shadick8, James R O'Dell9, Geoffrey M Thiele9, E William St Clair10, Christopher C Striebich7, Matthew B Hale5, Houman Khalili4, Franak Batliwalla4, Cynthia Aranow4, Meggan Mackay4, Betty Diamond4, Garry P Nolan1, Peter K Gregersen4, S Louis Bridges11.
Abstract
Rheumatoid arthritis (RA) is a systemic and incurable autoimmune disease characterized by chronic inflammation in synovial lining of joints. To identify the signaling pathways involved in RA, its disease activity, and treatment response, we adapted a systems immunology approach to simultaneously quantify 42 signaling nodes in 21 immune cell subsets (e.g., IFNα→p-STAT5 in B cells) in peripheral blood mononuclear cells (PBMC) from 194 patients with longstanding RA (including 98 patients before and after treatment), and 41 healthy controls (HC). We found multiple differences between patients with RA compared to HC, predominantly in cytokine-induced Jak/STAT signaling in many immune cell subsets, suggesting pathways that may be associated with susceptibility to RA. We also found that high RA disease activity, compared to low disease activity, was associated with decreased (e.g., IFNα→p-STAT5, IL-10→p-STAT1) or increased (e.g., IL-6→STAT3) response to stimuli in multiple cell subsets. Finally, we compared signaling in patients with established, refractory RA before and six months after initiation of methotrexate (MTX) or TNF inhibitors (TNFi). We noted significant changes from pre-treatment to post-treatment in IFNα→p-STAT5 signaling and IL-10→p-STAT1 signaling in multiple cell subsets; these changes brought the aberrant RA signaling profiles toward those of HC. This large, comprehensive functional signaling pathway study provides novel insights into the pathogenesis of RA and shows the potential of quantification of cytokine-induced signaling as a biomarker of disease activity or treatment response.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33444321 PMCID: PMC7808603 DOI: 10.1371/journal.pone.0244187
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240